Nautilus Biotechnology

Nautilus Biotechnology, Inc. operates as a life sciences company. The firm develops proteomics platform for analyzing and quantifying the human proteome. The company was founded by Sujal Patel and Parag Mallick in 2016 and is headquartered in Seattle, WA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Nautilus Biotechnology reports strong financials and strategic collaborations

Nautilus Biotechnology is strategically positioned with strong financials and key collaborations for future growth.
The company's focus on innovation and customer engagement sets the stage for a successful commercial launch in mid-2024.
Despite challenges like increasing expenses and supply chain issues, Nautilus is poised to capitalize on market opportunities.
CEO's vision of a highly differentiated product and market evolution aligns with the company's strategic direction.

Nautilus Biotechnology advances towards proteome access, strong financial position

Nautilus Biotechnology's Q1 2023 performance reflects strong advancements in its scientific and engineering objectives, positioning the company well for its upcoming platform launch in mid-2024. With a robust financial position and a focus on strategic investments, Nautilus is poised for long-term growth and innovation in the proteomics market.

Nautilus Biotechnology advances in proteomics with strong financial backing

Nautilus Biotechnology's Q2 performance reflects steady progress towards developing a groundbreaking proteomic platform, supported by active industry engagement and a strong financial position.
While facing challenges in managing operating expenses and executing on its technological vision, the company's strategic strengths and opportunities position it for future success.
With a clear focus on innovation and customer value, Nautilus is well-equipped to drive growth, deliver on its promises, and shape the future of proteomics.

Nautilus Biotechnology progresses in Q3, eyes market revolution and growth

Nautilus Biotechnology's Q3 performance reflects advancements in R&D, financial stability, and strategic partnerships.
The company's strengths lie in its innovative platform, expert team, and confidence in value proposition.
Challenges include competitive positioning, operational hurdles, and managing expenses effectively.
Opportunities for Nautilus Biotechnology include industry engagements, market penetration, and sustainable growth.

Nautilus Biotechnology advances Proteome Analysis Platform launch to 2025

Nautilus Biotechnology made progress in 2023 towards launching the Proteome Analysis Platform in 2025, despite a net loss of $17.0 million in Q4. The company's focus on scalability, reproducibility, and collaborations with key partners positions it well for future growth. Challenges in refining the platform's quality and milestones in protein decoding are being addressed to maximize long-term value.

Nautilus Biotechnology excels in proteomics, faces inquiries and growth

Nautilus Biotechnology demonstrated strong performance in proteomic data analysis and platform development in Q1 2024.
While facing challenges in addressing analyst inquiries and managing financial aspects, the company remains well-positioned.
Opportunities lie in leveraging positive feedback, advancing platform development, and engaging in global events for growth.

Nautilus Biotechnology progresses towards commercial launch amidst financial stability

Nautilus Biotechnology demonstrated strong performance and financial stability in Q2 2024, positioning itself for future growth and commercial success.
The company's focus on proteoforms, technological advancements, and strategic leadership are key strengths driving its competitive edge.
Challenges in meeting timelines, managing costs, securing funding, and navigating market competition require strategic focus and execution.
Opportunities in the growing proteomics market, technology advancements, partnerships, and market expansion offer avenues for future growth and success.

Nautilus Biotechnology reports robust Q3 performance and eyes market expansion

Nautilus Biotechnology's Q3 2024 earnings call highlighted strong financial performance, platform development progress, and strategic leadership appointments.
The company's focus on efficient cash management, extended cash runway, and future growth plans underscore a commitment to long-term success.
While facing challenges in probe development and commercialization, Nautilus Biotechnology is well-positioned to capitalize on opportunities in partnerships and market expansion.
Overall, Nautilus Biotechnology's emphasis on innovation, financial prudence, and market engagement sets a positive trajectory for future growth and industry impact.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Nautilus Biotechnology, Inc. is a life sciences company, which engages in the development of a proteomics platform for analyzing and quantifying the human proteome. Its products include Proteome Analysis System, Reagent Kits, and Software and Analysis. The company was founded by Sujal Patel and Parag Mallick in 2016 and is headquartered in Seattle, WA.

SEATTLE, April 18, 2023 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced it will report financial results for the first quarter before market open on Tuesday, May 2, 2023.

Nautilus Biotechnology to Announce First Quarter Financial Results on May 2, 2023

SEATTLE, March 23, 2023 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced the company will be participating in the upcoming B. Riley Securities' Disruptive Biotech Enabling Technologies – Proteomics, Virtual Conference.

Nautilus Biotechnology to Participate in B. Riley Securities' Disruptive Biotech Enabling Technologies – Proteomics, Virtual Conference

BARK

BigBear.ai Holdings

Penny stocks to watch right now. The post 3 Penny Stocks Under $3 To Watch In March appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

3 Penny Stocks Under $3 To Watch In March

Nautilus Biotechnology, Inc. (NASDAQ:NAUT ) Q4 2022 Earnings Conference Call February 23, 2023 8:30 AM ET Company Participants Sujal Patel - Co-Founder and CEO Anna Mowry - CFO Parag Mallick - Co-Founder and Chief Scientist Conference Call Participants Max Masucci - Cowen and Company Matthew Sykes - Goldman Sachs Brandon Couillard - Jefferies Tejas Savant - Morgan Stanley Operator Good day, and thank you for standing by. Welcome to the Nautilus Biotechnology Q4 and Full Year 2022 earnings conference call.

Nautilus Biotechnology, Inc. (NAUT) Q4 2022 Earnings Call Transcript

SEATTLE, Feb. 23, 2023 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single molecule proteome analysis platform, today reported financial results for the fourth quarter and fiscal year ended December 31, 2022.

Nautilus Biotechnology Reports Fourth Quarter and Fiscal Year 2022 Financial Results

SEATTLE, Feb. 21, 2023 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced the company will be participating in the upcoming 43rd Annual Cowen Health Care Conference.

Nautilus Biotechnology to Participate in the 43rd Annual Cowen Health Care Conference

SEATTLE, Jan. 26, 2023 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform, today announced it will report financial results for the fourth quarter and full year of 2022 before market open on Thursday, February 23, 2023.

Nautilus Biotechnology to Announce Fourth Quarter and Full Year 2022 Financial Results on February 23, 2023

Proteomics company opens new office in Southern California to facilitate ongoing research and team growth aimed at unlocking the potential of the proteome Proteomics company opens new office in Southern California to facilitate ongoing research and team growth aimed at unlocking the potential of the proteome

Nautilus Biotechnology Expands to San Diego

Collaboration enables TGen to gain access to data generated on prototype versions of Nautilus' next-generation proteome analysis platform to advance the study of a rare childhood cancer Collaboration enables TGen to gain access to data generated on prototype versions of Nautilus' next-generation proteome analysis platform to advance the study of a rare childhood cancer

Nautilus Biotechnology Partners with the Translational Genomics Research Institute (TGen) to Investigate Applications of Single-Molecule Proteomic Analysis in Diffuse Intrinsic Pontine Glioma (DIPG)

Sujal Patel has been here before. He weathered the 2009 recession as CEO of Isilon Systems, coming out the other end to sell his company the next year for $2.25 billion.

Biotech industry leaders share cautious optimism for 2023 amid downturn and layoffs

Nautilus Biotechnology, Inc. (NASDAQ:NAUT ) Q3 2022 Earnings Conference Call November 1, 2022 8:30 AM ET Company Participants Sujal Patel - Co-Founder and CEO Parag Mallick - Co-Founder and Chief Scientist Anna Mowry - CFO Conference Call Participants Max Masucci - Cowen David Delahunt - Goldman Sachs Brandon Couillard - Jefferies Operator Ladies and gentlemen, thank you for standing by, and welcome to the Nautilus Q3 2022 Earnings Call. [Operator Instructions] I would now like to turn the call over to your host [Alex Khan], Investor Relations.

Nautilus Biotechnology, Inc. (NAUT) Q3 2022 Earnings Call Transcript

SEATTLE, Nov. 01, 2022 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single molecule proteome analysis platform, today reported financial results for the third quarter ended September 30, 2022.

Nautilus Biotechnology Reports Third Quarter 2022 Financial Results

Adobe

Starbucks

Loop Media Inc

United Natural Foods

Insiders buying stocks generally indicates a positive outlook from investors most in the know.

Insider Buying at Starbucks, Adobe and 3 Other Stocks

SEATTLE, Sept. 23, 2022 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today announced the company will be participating in the upcoming Capital One Spatial Biology & Proteomics Summit taking place virtually on Wednesday, September 28, 2022.

Nautilus Biotechnology to Participate in the Capital One Spatial Biology & Proteomics Summit

Representatives of company developing platform for comprehensively quantifying the proteome to provide HUPO leadership with input on technology and product innovation Representatives of company developing platform for comprehensively quantifying the proteome to provide HUPO leadership with input on technology and product innovation

Nautilus Biotechnology Joins Human Proteome Organization (HUPO) Industrial Advisory Board

SEATTLE, Aug. 30, 2022 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today announced the company will be participating in the upcoming Morgan Stanley Global Healthcare Conference in New York, NY.

Nautilus Biotechnology to Participate in the Morgan Stanley Global Healthcare Conference

Nautilus Biotechnology, Inc. (NASDAQ:NAUT ) Q2 2022 Earnings Conference Call August 2, 2022 8:30 AM ET Company Participants Sujal Patel - Founder and Chief Executive Officer Anna Mowry - Chief Financial Officer Parag Mallick - Founder and Chief Scientist Conference Call Participants Stephanie Yan - Cowen and Company, LLC Tejas Savant - Morgan Stanley David Delahunt - Goldman Sachs Operator Thank you for standing by, and welcome to the Nautilus Biotechnology Second Quarter 2022 Earnings Conference Call. At this time, all participants are in a listen-only mode.

Nautilus Biotechnology, Inc. (NAUT) CEO Sujal Patel on Q2 2022 Results - Earnings Call Transcript

SEATTLE, Aug. 02, 2022 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single molecule proteome analysis, today reported financial results for the second quarter ended June 30, 2022.

Nautilus Biotechnology Reports Second Quarter 2022 Financial Results

SEATTLE, July 13, 2022 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today announced it will report financial results for the second quarter 2022 before market open on Tuesday, August 2nd, 2022.

Nautilus Biotechnology to Announce Second Quarter 2022 Financial Results on August 2, 2022

Nautilus Biotechnology, Inc. (NASDAQ:NAUT ) Q1 2022 Earnings Conference Call May 3, 2022 8:30 AM ET Company Participants Sujal Patel - Co-Founder & CEO Anna Mowry - CFO Parag Mallick - Co-Founder & Chief Scientific Officer Conference Call Participants Matt Kim - Jefferies Stephanie Yan - Cowen & Company Edmund Tu - Morgan Stanley David Delahunt - Goldman Sachs Operator Thank you for standing by, and welcome to the Nautilus Q1 2022 Earnings Conference Call. At this time, all participants are in a listen-only mode.

Nautilus Biotechnology, Inc. (NAUT) CEO Sujal Patel on Q1 2022 Results - Earnings Call Transcript

SEATTLE, May 03, 2022 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single molecule proteome analysis, today reported financial results for the first quarter ended March 31, 2022.

Nautilus Biotechnology Reports First Quarter 2022 Financial Results

SEATTLE, April 07, 2022 (GLOBE NEWSWIRE) -- Nautilus Biotechnology, Inc. (NASDAQ: NAUT; or “Nautilus”), a company pioneering a single-molecule protein analysis platform for quantifying the proteome, today announced it will report financial results for the first quarter 2022 before market open on Tuesday, May 3rd, 2022.

Nautilus Biotechnology to Announce First Quarter 2022 Financial Results on May 3, 2022

• Co-founder and Chief Scientist Parag Mallick, Ph.D., to present lecture at Annual Congress of the European Proteomics Association (EuPA)  • Associate Director Greg Kapp, Ph.D., to present poster at American Association for Cancer Research (AACR) Annual Meeting

Nautilus Biotechnology to Present at EuPA and AACR Meetings

Schrödinger President of R&D, Therapeutics brings extensive leadership in commercializing breakthrough biotechnologies to company developing platform for comprehensively quantifying the proteome to enable fundamental advancements in biomedicine Schrödinger President of R&D, Therapeutics brings extensive leadership in commercializing breakthrough biotechnologies to company developing platform for comprehensively quantifying the proteome to enable fundamental advancements in biomedicine

Nautilus Biotechnology Appoints Karen Akinsanya, Ph.D., to Board of Directors

Nautilus Biotechnology, Inc. (NAUT) CEO Sujal Patel on Q4 2021 Results - Earnings Call Transcript

News for Nautilus Biotechnology Stock (NAUT)